Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04450407 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3209590 in Participants With Type 1 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
NCT04450407 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 266 participants.
The verdict
NCT04450407, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
Interventions
- DRUG LY3209590
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04450407
The ClinicalTrials.gov registry entry for NCT04450407 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY3209590 is the first listed.
NCT04450407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04450407 about?
NCT04450407 is a clinical study titled "A Study of LY3209590 in Participants With Type 1 Diabetes". The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
What is the current status of trial NCT04450407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2020-07-06. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04450407?
The interventions under investigation include: LY3209590 (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT04450407?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.